EE04199B1 - Rekombinantne MVA viirus, isoleeritud eukarüootnerakk ja vaktsiin ning nende kasutamine - Google Patents
Rekombinantne MVA viirus, isoleeritud eukarüootnerakk ja vaktsiin ning nende kasutamineInfo
- Publication number
- EE04199B1 EE04199B1 EE9700344A EE9700344A EE04199B1 EE 04199 B1 EE04199 B1 EE 04199B1 EE 9700344 A EE9700344 A EE 9700344A EE 9700344 A EE9700344 A EE 9700344A EE 04199 B1 EE04199 B1 EE 04199B1
- Authority
- EE
- Estonia
- Prior art keywords
- recombinant mva
- vaccine
- eukaryotic cell
- mva virus
- isolated eukaryotic
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 title 1
- 210000003527 eukaryotic cell Anatomy 0.000 title 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
- C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
- C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1247—DNA-directed RNA polymerase (2.7.7.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Manufacturing & Machinery (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK78295 | 1995-07-04 | ||
PCT/EP1996/002926 WO1997002355A1 (en) | 1995-07-04 | 1996-07-03 | Recombinant mva virus, and the use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EE9700344A EE9700344A (et) | 1998-06-15 |
EE04199B1 true EE04199B1 (et) | 2003-12-15 |
Family
ID=8097499
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EE9700344A EE04199B1 (et) | 1995-07-04 | 1996-07-03 | Rekombinantne MVA viirus, isoleeritud eukarüootnerakk ja vaktsiin ning nende kasutamine |
EEP200300331A EE05138B1 (et) | 1995-07-04 | 1996-07-03 | Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin |
EEP200300332A EE04753B1 (et) | 1995-07-04 | 1996-07-03 | Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse hTyr-proteiini valmistamiseks ning vaktsiin |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200300331A EE05138B1 (et) | 1995-07-04 | 1996-07-03 | Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin |
EEP200300332A EE04753B1 (et) | 1995-07-04 | 1996-07-03 | Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse hTyr-proteiini valmistamiseks ning vaktsiin |
Country Status (27)
Country | Link |
---|---|
US (6) | US6440422B1 (es) |
EP (3) | EP1312678B1 (es) |
JP (3) | JP4312260B2 (es) |
KR (1) | KR19990028617A (es) |
CN (3) | CN1154742C (es) |
AT (3) | ATE239796T1 (es) |
AU (1) | AU721735B2 (es) |
BR (1) | BR9609303B8 (es) |
CA (3) | CA2225278C (es) |
CZ (1) | CZ292460B6 (es) |
DE (3) | DE69635172T2 (es) |
DK (3) | DK1312679T3 (es) |
EE (3) | EE04199B1 (es) |
ES (3) | ES2249647T3 (es) |
HK (2) | HK1009830A1 (es) |
HU (2) | HU224061B1 (es) |
IL (5) | IL122120A (es) |
MX (1) | MX9800025A (es) |
NO (1) | NO322476B1 (es) |
NZ (1) | NZ313597A (es) |
PL (1) | PL186857B1 (es) |
PT (1) | PT836648E (es) |
RU (1) | RU2198217C2 (es) |
SI (3) | SI1312678T1 (es) |
TW (2) | TW575664B (es) |
UA (3) | UA68327C2 (es) |
WO (1) | WO1997002355A1 (es) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
US7118754B1 (en) * | 1996-07-30 | 2006-10-10 | Transgene S.A. | Pharmaceutical composition for treating papillomavirus tumors and infection |
EP0951555A2 (en) * | 1996-09-24 | 1999-10-27 | Bavarian Nordic Research Institute A/S | Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines |
MY119381A (en) * | 1996-12-24 | 2005-05-31 | Gsf Forschungszentrum Umwelt | Recombinant mva virus, and the use thereof |
US6969609B1 (en) * | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
FR2784997A1 (fr) * | 1998-10-22 | 2000-04-28 | Transgene Sa | Materiel biologique pour la preparation de compositions pharmaceutiques destinees au traitement de mammiferes |
US20040265324A1 (en) * | 1999-03-23 | 2004-12-30 | Cardosa Mary Jane | Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines |
DE60040662D1 (de) * | 1999-05-28 | 2008-12-11 | Helmholtz Zentrum Muenchen | Vektor zur integration von heterologen sequenzen in poxvirusgenomen |
US20150231227A1 (en) * | 2000-03-02 | 2015-08-20 | Emory University | Compositions and methods for generating an immune response |
CA2397675C (en) * | 2000-03-14 | 2012-11-13 | Anton Mayr | Altered strain of the modified vaccinia virus ankara (mva) |
DE10042598A1 (de) * | 2000-08-30 | 2002-03-28 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS |
WO2002031168A2 (en) * | 2000-10-10 | 2002-04-18 | Genstar Therapeutics | Minimal adenoviral vector and recombinant vaccines based thereon |
EE05680B1 (et) | 2000-11-23 | 2013-10-15 | Bavarian Nordic A/S | Muundatud vaktsiiniaviirus, selle valmistamine ja kasutamine, seda sisaldav farmatseutiline kompositsioon ning vaktsiin |
US7628980B2 (en) | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
US7740863B2 (en) | 2001-04-06 | 2010-06-22 | Merial | Recombinant vaccine against West Nile Virus |
DE10143490C2 (de) * | 2001-09-05 | 2003-12-11 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen |
DE10144664B4 (de) * | 2001-09-11 | 2005-06-09 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon |
CA2466413C (en) | 2001-12-04 | 2014-11-04 | Bavarian Nordic A/S | Flavivirus ns1 subunit vaccine |
UA77735C2 (en) * | 2001-12-20 | 2007-01-15 | Bavarian Nordic As | Method for recovery of poxviruses from infected cells |
KR101028937B1 (ko) * | 2002-04-19 | 2011-04-12 | 버베리안 노딕 에이/에스 | 신생아의 백신접종용 변형 백시니아 바이러스 안카라 |
PL218318B1 (pl) | 2002-05-16 | 2014-11-28 | Bavarian Nordic As | Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych |
NZ536500A (en) * | 2002-05-16 | 2008-01-31 | Bavarian Nordic As | Expression of genes in modified vaccinia virus ankara by using the cowpox ATI promoter |
US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
EA009008B1 (ru) | 2002-09-05 | 2007-10-26 | Бавариан Нордик А/С | Способ амплификации вируса оспы |
DE10249390A1 (de) * | 2002-10-23 | 2004-05-13 | Ruprecht-Karls-Universität Heidelberg | Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria |
CN1717488A (zh) * | 2002-11-25 | 2006-01-04 | 巴法里安诺迪克有限公司 | 包含至少两个牛痘ati启动子的重组痘病毒 |
CN1723285B (zh) * | 2003-02-18 | 2013-01-02 | 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 | 重组的mva及其产生方法 |
US7638134B2 (en) * | 2003-02-20 | 2009-12-29 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Insertion sites in fowlpox vectors |
DE602004018284D1 (de) | 2003-03-27 | 2009-01-22 | Ottawa Health Research Inst | Mutante vesicular stomatitis viren und deren verwendungen |
US7731974B2 (en) | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
WO2004093905A1 (en) * | 2003-04-16 | 2004-11-04 | City Of Hope | Human cytomegalovirus antigens expressed in mva and methods of use |
GB2402391A (en) * | 2003-06-04 | 2004-12-08 | Oxxon Pharmaccines Ltd | Fowlpox recombinant genome |
DE602004031681D1 (de) | 2003-07-21 | 2011-04-14 | Transgene Sa | Multifunktionelle Cytokine |
US20100189747A1 (en) * | 2003-07-31 | 2010-07-29 | Raymond Weinstein | Compositions and methods for treating or preventing hiv infection |
EP1518932A1 (en) * | 2003-09-29 | 2005-03-30 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Modified vaccinia virus Ankara (MVA) mutant and use thereof |
EP1845164B1 (en) | 2003-11-24 | 2010-06-16 | Bavarian Nordic A/S | Promoters for expression in modified vaccinia virus ankara |
US7638132B2 (en) | 2003-12-05 | 2009-12-29 | National University Corporation Hokkaido University | Highly safe smallpox vaccine virus and vaccinia virus vector |
EP1683870A1 (en) * | 2005-01-24 | 2006-07-26 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Vaccines based on the use of MVA |
US20090269365A1 (en) * | 2005-04-20 | 2009-10-29 | University Of Washington | Immunogenic vaccinia peptides and methods of using same |
EP2023954B1 (en) * | 2006-05-19 | 2013-07-17 | Sanofi Pasteur, Inc. | Immunological composition |
EP2029756B1 (en) * | 2006-06-20 | 2016-11-09 | Transgene S.A. | Process for producing poxviruses and poxvirus compositions |
WO2008076157A2 (en) * | 2006-09-08 | 2008-06-26 | Duke University | Modified vaccinia ankara virus vaccine |
JP5606067B2 (ja) * | 2006-09-15 | 2014-10-15 | オタワ ホスピタル リサーチ インスティテュート | 腫瘍崩壊性ラブドウイルス |
DK2073837T3 (da) | 2006-10-06 | 2014-09-29 | Bavarian Nordic Inc | Rekombinant modificeret vaccinia-ankara-virus, der koder for et her-2-antigen, i kombination med en taxan til anvendelse til behandling af cancer |
US20080241139A1 (en) * | 2006-10-31 | 2008-10-02 | Regents Of The University Of Colorado | Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity |
AU2008211199A1 (en) * | 2007-01-26 | 2008-08-07 | The Regents Of The University Of Colorado | Methods of modulating immune function |
EP2208737B1 (en) | 2007-05-03 | 2017-07-05 | Lysomab GmbH | Complement factor H-derived short consensus repeat-antibody constructs |
US8003363B2 (en) | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
US8003364B2 (en) * | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
JP2010526546A (ja) * | 2007-05-14 | 2010-08-05 | バヴァリアン・ノルディック・アクティーゼルスカブ | ワクシニアウイルス系及び組換えワクシニアウイルス系ワクチンの精製 |
US20100285050A1 (en) * | 2007-10-05 | 2010-11-11 | Isis Innovation Limited | Compositions and Methods |
BRPI0800485B8 (pt) * | 2008-01-17 | 2021-05-25 | Univ Minas Gerais | vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose |
BRPI0908474A2 (pt) | 2008-02-12 | 2016-07-26 | Sanofi Pasteur Ltd | métodos de uso de cromatografia de troca de íon e de filtração de gel para purificação de vírus causador da catapora |
WO2009152969A1 (en) * | 2008-06-20 | 2009-12-23 | Bavarian Nordic A/S | Recombinant modified vaccinia virus measles vaccine |
US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
CA2760315C (en) | 2009-04-30 | 2019-05-28 | Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) | Modified immunization vectors |
TWI555531B (zh) * | 2009-08-07 | 2016-11-01 | 傳斯堅公司 | 用以治療b型肝炎病毒(hbv)感染之組成物 |
US9005632B2 (en) | 2009-11-20 | 2015-04-14 | Takeda Vaccines, Inc. | Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains |
US9011874B2 (en) | 2009-11-20 | 2015-04-21 | Takeda Vaccines, Inc. | Compositions, methods and uses for poxvirus elements in vaccine constructs |
EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
GB201006405D0 (en) | 2010-04-16 | 2010-06-02 | Isis Innovation | Poxvirus expression system |
US20110262965A1 (en) | 2010-04-23 | 2011-10-27 | Life Technologies Corporation | Cell culture medium comprising small peptides |
EP2668201A2 (en) | 2011-01-28 | 2013-12-04 | Sanofi Pasteur SA | Immunological compositions comprising hiv gp41 polypeptide derivatives |
WO2012151272A2 (en) | 2011-05-02 | 2012-11-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
RS57397B8 (sr) | 2011-06-10 | 2020-01-31 | Univ Oregon Health & Science | Cmv glikoproteini i rekombinantni vektori |
PL2739293T3 (pl) | 2011-08-05 | 2020-11-16 | Sillajen Biotherapeutics, Inc. | Sposoby i kompozycje wytwarzania wirusa krowianki |
EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
ES2683820T3 (es) * | 2011-09-26 | 2018-09-28 | Theravectys | Uso de proteínas GAG no de subtipo B para encapsidación lentiviral |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
EP2788021B1 (en) | 2011-12-09 | 2017-01-18 | Bavarian Nordic A/S | Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
CA2878800A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterial antigen vaccine |
WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
JP6430949B2 (ja) | 2012-10-23 | 2018-11-28 | エモリー ユニバーシティ | Gm−csfとil−4のコンジュゲート、組成物、ならびにそれに関連する方法 |
US20140286981A1 (en) | 2013-03-14 | 2014-09-25 | Wisconsin Alumni Research Foundation | Broadly reactive mosaic peptide for influenza vaccine |
DE102013004595A1 (de) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV-Impfstoffe |
EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
WO2015104380A1 (en) | 2014-01-09 | 2015-07-16 | Transgene Sa | Fusion of heterooligomeric mycobacterial antigens |
GB201412494D0 (en) | 2014-07-14 | 2014-08-27 | Ospedale San Raffaele And Fond Telethon | Vector production |
BR112017005917A2 (pt) | 2014-09-26 | 2017-12-12 | Beth Israel Deaconess Medical Ct Inc | processos e composições para indução de imunidade protetora contra infecção com o vírus da imunodeficiência humana |
US11701418B2 (en) | 2015-01-12 | 2023-07-18 | Geovax, Inc. | Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40) |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
TWI792091B (zh) | 2015-12-15 | 2023-02-11 | 荷蘭商傑森疫苗防護公司 | 人類免疫缺陷病毒抗原、載體、組成物、及其使用方法 |
US11278607B2 (en) | 2016-01-08 | 2022-03-22 | Geovax, Inc. | Compositions and methods for generating an immune response to a tumor associated antigen |
WO2017136419A1 (en) | 2016-02-03 | 2017-08-10 | Geovax Inc. | Compositions and methods for generating an immune response to a flavivirus |
IL261321B2 (en) * | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors |
WO2017191147A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
CN109219448B (zh) | 2016-06-16 | 2022-09-20 | 扬森疫苗与预防公司 | Hiv疫苗配制品 |
US10307477B2 (en) | 2016-09-02 | 2019-06-04 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
JP7178344B2 (ja) | 2016-09-15 | 2022-11-25 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 三量体安定化hivエンベロープタンパク質変異 |
WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
KR20200015759A (ko) | 2017-06-15 | 2020-02-12 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법 |
JP7334124B2 (ja) | 2017-06-21 | 2023-08-28 | トランジェーヌ | 個別化ワクチン |
KR20200031655A (ko) | 2017-07-19 | 2020-03-24 | 얀센 백신스 앤드 프리벤션 비.브이. | 삼량체를 안정화하는 hiv 엔벨로프 단백질 돌연변이 |
WO2019018724A1 (en) | 2017-07-21 | 2019-01-24 | Janssen Vaccines & Prevention B.V. | METHODS FOR SAFE INDUCTION OF MULTICLADED CROSS-IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN BEINGS |
US20190083620A1 (en) | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
CN111315407B (zh) | 2018-09-11 | 2023-05-02 | 上海市公共卫生临床中心 | 一种广谱抗流感疫苗免疫原及其应用 |
WO2020237052A1 (en) | 2019-05-22 | 2020-11-26 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
CA3151982A1 (en) * | 2019-10-16 | 2021-04-22 | Stephen H. Thorne | Producer viruses for generation of retroviruses in situ |
WO2021094984A1 (en) | 2019-11-14 | 2021-05-20 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
WO2021260065A1 (en) | 2020-06-24 | 2021-12-30 | Consejo Superior De Investigaciones Científicas (Csic) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
EP3928789A1 (en) | 2020-06-24 | 2021-12-29 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
EP4329786A1 (en) | 2021-04-30 | 2024-03-06 | KaliVir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
EP4108257A1 (en) | 2021-06-23 | 2022-12-28 | Consejo Superior De Investigaciones Científicas | Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein |
EP4358999A1 (en) | 2021-06-23 | 2024-05-01 | Consejo Superior De Investigaciones Científicas | Mva-based vaccine expressing a prefusion-stabilized sars-cov-2 s protein |
WO2023077147A2 (en) | 2021-11-01 | 2023-05-04 | Pellis Therapeutics, Inc. | T-cell vaccines for patients with reduced humoral immunity |
WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
WO2023220283A1 (en) | 2022-05-12 | 2023-11-16 | Pellis Therapeutics, Inc. | Poxvirus adjuvant for t-cell vaccination |
EP4316514A1 (en) | 2022-08-03 | 2024-02-07 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vectors and their use as vaccine against sars-cov-2 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE787901A (fr) | 1971-09-11 | 1972-12-18 | Freistaat Bayern Represente Pa | Vaccin antivariolique |
JPH0795954B2 (ja) | 1982-11-30 | 1995-10-18 | アメリカ合衆国 | 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法 |
US5679511A (en) * | 1986-10-06 | 1997-10-21 | Donald Guthrie Foundation For Medical Research, Inc. | CDNA clones for a regulatory protein in the melanin-production pathway |
CA1341245C (en) * | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
US5221610A (en) * | 1988-05-26 | 1993-06-22 | Institut Pasteur | Diagnostic method and composition for early detection of HIV infection |
CN1042564A (zh) * | 1988-11-11 | 1990-05-30 | 中国科学院上海生物化学研究所 | 乙肝疫苗的制备方法及其制品 |
JPH03271233A (ja) | 1990-03-19 | 1991-12-03 | Inst Pasteur | ウイルスエンベロープ糖タンパク質及びその糖タンパク質の中和エピトープに対応するペプチドの間の相乗作用による、ウイルス性感染に対する防御の誘発 |
JPH07501052A (ja) * | 1991-10-28 | 1995-02-02 | インスティチュート・パスツール | ウイルスエンベロープタンパク質と糖タンパク質の中和エピトープに相当するペプチドとの間の相乗作用によるウイルス感染に対する防御の誘発 |
DK0687180T3 (da) * | 1992-12-22 | 2000-11-27 | Ludwig Inst Cancer Res | Fremgangsmåde til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-anti |
US5620886A (en) * | 1993-03-18 | 1997-04-15 | Ludwig Institute For Cancer Research | Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 |
JP3814828B2 (ja) * | 1993-10-19 | 2006-08-30 | 味の素株式会社 | Hivに対する免疫応答を誘導できるペプチド及び該ペプチドを含む抗aids予防・治療剤 |
US5676950A (en) * | 1994-10-28 | 1997-10-14 | University Of Florida | Enterically administered recombinant poxvirus vaccines |
UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
-
1996
- 1996-03-07 UA UA97126424A patent/UA68327C2/uk unknown
- 1996-07-03 MX MX9800025A patent/MX9800025A/es unknown
- 1996-07-03 CN CNB961952547A patent/CN1154742C/zh not_active Expired - Lifetime
- 1996-07-03 ES ES03001378T patent/ES2249647T3/es not_active Expired - Lifetime
- 1996-07-03 ES ES03001379T patent/ES2249648T3/es not_active Expired - Lifetime
- 1996-07-03 CA CA002225278A patent/CA2225278C/en not_active Expired - Lifetime
- 1996-07-03 EP EP03001378A patent/EP1312678B1/en not_active Expired - Lifetime
- 1996-07-03 KR KR1019970709939A patent/KR19990028617A/ko not_active Application Discontinuation
- 1996-07-03 DK DK03001379T patent/DK1312679T3/da active
- 1996-07-03 NZ NZ313597A patent/NZ313597A/xx not_active IP Right Cessation
- 1996-07-03 DK DK03001378T patent/DK1312678T3/da active
- 1996-07-03 WO PCT/EP1996/002926 patent/WO1997002355A1/en active Application Filing
- 1996-07-03 AT AT96925654T patent/ATE239796T1/de active
- 1996-07-03 RU RU98101904/13A patent/RU2198217C2/ru active
- 1996-07-03 CN CNA2005101248556A patent/CN1782071A/zh active Pending
- 1996-07-03 HU HU9802217A patent/HU224061B1/hu active IP Right Grant
- 1996-07-03 AT AT03001378T patent/ATE304057T1/de active
- 1996-07-03 UA UA20031212892A patent/UA75411C2/uk unknown
- 1996-07-03 ES ES96925654T patent/ES2199294T3/es not_active Expired - Lifetime
- 1996-07-03 SI SI9630718T patent/SI1312678T1/sl unknown
- 1996-07-03 DE DE69635172T patent/DE69635172T2/de not_active Expired - Lifetime
- 1996-07-03 AU AU66110/96A patent/AU721735B2/en not_active Expired
- 1996-07-03 EE EE9700344A patent/EE04199B1/xx unknown
- 1996-07-03 CA CA2596274A patent/CA2596274C/en not_active Expired - Lifetime
- 1996-07-03 CZ CZ19974241A patent/CZ292460B6/cs not_active IP Right Cessation
- 1996-07-03 PT PT96925654T patent/PT836648E/pt unknown
- 1996-07-03 SI SI9630623T patent/SI0836648T1/xx unknown
- 1996-07-03 BR BRPI9609303-0B8A patent/BR9609303B8/pt active IP Right Grant
- 1996-07-03 UA UA20031212890A patent/UA75410C2/uk unknown
- 1996-07-03 CA CA2608864A patent/CA2608864C/en not_active Expired - Lifetime
- 1996-07-03 HU HU0402350A patent/HU229261B1/hu unknown
- 1996-07-03 DK DK96925654T patent/DK0836648T3/da active
- 1996-07-03 PL PL96324347A patent/PL186857B1/pl unknown
- 1996-07-03 DE DE69628011T patent/DE69628011T2/de not_active Expired - Lifetime
- 1996-07-03 JP JP50482497A patent/JP4312260B2/ja not_active Expired - Lifetime
- 1996-07-03 SI SI9630719T patent/SI1312679T1/sl unknown
- 1996-07-03 EP EP96925654A patent/EP0836648B1/en not_active Expired - Lifetime
- 1996-07-03 AT AT03001379T patent/ATE304058T1/de active
- 1996-07-03 EP EP03001379A patent/EP1312679B8/en not_active Expired - Lifetime
- 1996-07-03 EE EEP200300331A patent/EE05138B1/xx unknown
- 1996-07-03 DE DE69635173T patent/DE69635173T2/de not_active Expired - Lifetime
- 1996-07-03 IL IL12212096A patent/IL122120A/xx not_active IP Right Cessation
- 1996-07-03 EE EEP200300332A patent/EE04753B1/xx unknown
- 1996-07-03 CN CN2004100367144A patent/CN1554764B/zh not_active Expired - Lifetime
- 1996-12-31 TW TW085116379A patent/TW575664B/zh not_active IP Right Cessation
- 1996-12-31 TW TW092116681A patent/TWI245075B/zh not_active IP Right Cessation
-
1998
- 1998-01-02 NO NO19980026A patent/NO322476B1/no not_active IP Right Cessation
- 1998-01-02 US US09/002,443 patent/US6440422B1/en not_active Expired - Lifetime
- 1998-09-15 HK HK98110632A patent/HK1009830A1/xx not_active IP Right Cessation
-
2002
- 2002-05-15 US US10/147,284 patent/US7198934B2/en not_active Expired - Fee Related
-
2004
- 2004-09-28 IL IL164318A patent/IL164318A/en not_active IP Right Cessation
-
2005
- 2005-01-11 HK HK05100216.3A patent/HK1068015A1/xx not_active IP Right Cessation
-
2006
- 2006-09-19 US US11/523,004 patent/US20070071769A1/en not_active Abandoned
- 2006-09-19 US US11/523,030 patent/US20070071770A1/en not_active Abandoned
- 2006-09-19 US US11/522,889 patent/US8153138B2/en not_active Expired - Fee Related
-
2007
- 2007-03-12 JP JP2007062631A patent/JP4764367B2/ja not_active Expired - Lifetime
- 2007-03-12 JP JP2007062630A patent/JP4764366B2/ja not_active Expired - Lifetime
-
2009
- 2009-12-01 IL IL202448A patent/IL202448A0/en unknown
-
2010
- 2010-06-14 US US12/814,602 patent/US8197825B2/en not_active Expired - Fee Related
-
2011
- 2011-05-17 IL IL212933A patent/IL212933A0/en unknown
-
2012
- 2012-05-02 IL IL219528A patent/IL219528A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE04199B1 (et) | Rekombinantne MVA viirus, isoleeritud eukarüootnerakk ja vaktsiin ning nende kasutamine | |
ATE236262T1 (de) | Rekombinanter schweinepocken-virus | |
NO20091761L (no) | Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav | |
NZ333975A (en) | Recombinant swinepox virus | |
HUP9802587A2 (hu) | Glükózzal indukálható rekombináns virális vektor, ezt tartalmazó gyógyszerkészítmény és ezzel transzformált sejtek | |
MY134484A (en) | Recombinant mva virus, and the use thereof | |
MY119381A (en) | Recombinant mva virus, and the use thereof | |
MY157873A (en) | Recombinant mva virus, and the use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB4A | Valid patent at the end of a year |
Effective date: 20031231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20041231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20051231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20061231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20071231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |